Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS
· Real-Time Price · USD
8.16
0.00 (0.00%)
At close: Jun 24, 2025, 3:59 PM
Regulus Therapeutics Revenue Breakdown
| Period Ending | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Sep 30, 2018 | Jun 30, 2018 |
|---|---|---|---|---|---|---|
| Strategic Alliances and Collaborations Revenue | 6K | 18K | 18K | 6.78M | 18K | 18K |
| Strategic Alliances and Collaborations Revenue Growth | -66.67% | 0.00% | -99.73% | +37555.56% | 0.00% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.72M | 4.07M | 3.86M | 3.93M | 2.79M | 2.52M | 2.64M | 2.34M | 2.44M | 2.22M | 2.25M | 2.47M | 2.89M | 2.55M | 2.5M | 2.49M | 2.48M | 2.08M | 2.06M | 2.25M | 2.42M | 2.36M | 2.57M | 2.85M | 3.53M | 2.75M | 2.99M | 3.35M | 3.77M | 3.26M | 2.74M | 7.06M | 3.96M | 4.78M | 4.84M | 3.66M | 5.1M | 5.43M | 4.25M | 5.81M | 3.64M |
| Selling, General, and Administrative Revenue Growth | -8.71% | +5.46% | -1.73% | +41.10% | +10.69% | -4.55% | +12.74% | -4.30% | +10.14% | -1.51% | -8.67% | -14.64% | +13.29% | +1.88% | +0.64% | +0.40% | +19.25% | +0.92% | -8.65% | -6.94% | +2.50% | -8.09% | -9.79% | -19.33% | +28.71% | -8.29% | -10.63% | -11.24% | +15.77% | +19.12% | -61.23% | +78.25% | -17.23% | -1.22% | +32.15% | -28.20% | -5.97% | +27.84% | -26.99% | +59.55% | n/a |
| Research and Development Revenue | 6.82M | 9.67M | 11.35M | 8.24M | 6.04M | 5.71M | 5.49M | 4.98M | 4.92M | 4.71M | 5.31M | 4.71M | 3.68M | 4.41M | 5.92M | 4.15M | 3.32M | 3.95M | 4.04M | 4.24M | 3.12M | 2.09M | 2.44M | 1.84M | 5.98M | 5.25M | 6.88M | 10.01M | 11.83M | 10.46M | 12.7M | 14.28M | 15.75M | 14.98M | 14.55M | 18.01M | 16.76M | 12.79M | 10.96M | 19.2M | 13.43M |
| Research and Development Revenue Growth | -29.50% | -14.76% | +37.71% | +36.42% | +5.83% | +3.99% | +10.29% | +1.04% | +4.50% | -11.24% | +12.79% | +27.97% | -16.56% | -25.46% | +42.53% | +25.00% | -15.97% | -2.11% | -4.86% | +36.01% | +49.23% | -14.34% | +32.90% | -69.31% | +13.85% | -23.61% | -31.30% | -15.34% | +13.02% | -17.58% | -11.07% | -9.36% | +5.16% | +2.92% | -19.18% | +7.41% | +31.03% | +16.68% | -42.89% | +43.00% | n/a |